In summary, we characterized how CCL3 secreted by MM cells in an autocrine manner can drive M2 polarization and recruit CCR5 to the tumor area through paracrine signaling, thereby promoting myeloma progression and inducing drug resistance. The gene discussed is CCL3; the disease is plasma cell myeloma.